PTC/SB/08a (07-09)
Approved for use through 07/31/2012, OM8 0651-0031
U.S. Pasent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known	
	Application Number	10/521928
INFORMATION DISCLOSURE	Filing Date	July 29, 2003
STATEMENT BY APPLICANT	First Named Inventor	Bhatnagar, Ajay S. et al.
(Use as many sheets as necessary)	Art unit	1627
***************************************	Examiner Name	Javanmard, Sahar
Sheet 1 of 2	Attorney Docket Number	PAT032602-US-PCT

U.S. PATENT DOCUMENTS						
Examinar C	Cité No.	Document Number Number-Kind Code ^{2 of News}	Publication Date MM-DD-YYYY	Name of Patentee or	Plages, Columns, Lines, Where Relevant Passagns or Relevan Pigures Appeal	
inkas'	No."	Normber-Kind Code ^{) of reserv}	MM-DD-YYYY	Applicant of Oiled Document		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-		······································		
		US-				
		US-				
		US-				
		US-				
		US-		***************************************		
	1	US-				
		us-		······································		

		FOREI	GN PATENT DOC	UMENTS		
Examine: Citie Foreign: Patent Document Publishation Country Gode* Number* Kind Code* Number*		Foreign Patern Document	Publication Date	Name of Patertiee or	Pages, Columns, Lines.	
	MM-00;YYYY	Applicant of Clied Document	Pages, Columns, Lines. Where Refevant Passages or Refevant Figures Appear			
		JP62212369 (Abstract)	9/18/1987			E
						Ī
						E
						[
						Ī
	T			······································		T

Signature	Considered
	lat if reference considered, whether or not obtation is in conformance with MPEP 609. Draw at time through obtation if not in conformance

See Kind Codies of USPTO Patient Documents at www.uspto.gov or MPEP 901.54. * Enter Office that issued the document, by the two letter code WIPO Standard ST.3. For Japanese pasent documents, the indication of the year of the region of the Emperor must procede the sental number of the patent securement. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.57 and 1.96. The information is required to obtain or retain a benefit by the public which is to file land by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 fours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of sine you require to complete this form and/or suggestions for reducing this burden, should be sens to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 67/51/2012, OMB 9651-9931 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Regulation Act of 1986, no persons are required to respond to a collection of arthrmation unless it contains a valvi OMB contain rumber

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/521928		
1	NFORMATIO	N DISCL	OSURE	Filing Date	July 29, 2003		
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Bhatnagar, Ajay S. et al.		
				Art unit	1627		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				Examiner Name	Javanmard, Sahar		
Sneet	2	of	2	Attorney Docket Number	PAT032602-US-PCT		

		NON PATENT LITERATURE DOCUMENTS	
Examine: Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tale of the article (when appropriate), take of the item blank, magazans, journal, servel, syndronoum, catalog, etc.), cate, pagets), volume-levue numbersis, publisher, etw analtor country where published.	10
		Cohen, Martin H et al., "Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer", Clinical Cancer Research, Vol 8, pp. 66-669, 2002	
		Coleman R.E., "Metastatic bone disease: clinical features, pathophysiology and treatment strategues", Cancer Treatment Reviews, Vol. 27, pp. 165-178, 2001	C
		Hillner, Bruce E. et al., "American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Canoer". Journal of Clinical Oncology, Vol. 16, No 6, pp. 1378-1391, 2000	C
		Chinese New Drugs Journal, Vol. 8, No. 6, pp 374-376, 1999 (Abstract)	E
		Neville, Webbs, H. L. [Reprint Author): Lefley, D.; Coleman, R.E., Hoten, I., Bone (New York), Vol. 33, No. 3, Suppl. 1, pp. 558 559, Meeting Info.: 11° and Valledictory Workshop on Cell Ediogry of Bone and Cartilage in Health and Disease, Palacetinal, March 18-12, 2006 CODEN, BONED, LSBN, 875-92882.	C
			C
			C
			C
			С
			Е
			L
			E
			C
			Ľ
			C
			L
			E
			E
			L
			I

lignature		Consi	dered		
EXAMINER:	initial if reference considered, whether or not citation is in conformance with N	IPEP 609.	Draw a line	s through esistion	if not in conterman

**E-NAMINHEH: Introd is reported consistency with consistency of our classifiers in an extractionance with term's copie. Can'd a man energy consistency in a many consistency and not considered. Enclose copy of the is from with the man communication of applicant.

*Applicant's unique obtainor assignation number (oplicinal). *Applicant is to plazar a check mark here if English language Translation is attached.

*Applicant's unique obtainor assignation number (oplicinal). *Applicant is to plazar a check mark here if English language Translation is attached.

**Interview of the interview of the int

complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time well vary depending upon the individual cases. Any comments or the amount of time you require to complete this form and/or suggestions for reducing this burden, strough to see to time Online information Officer, U.S. Patient and Trademask Office, P.O. Box 14(5), Avancanca, M.R. 2023-14(5). DO NOT SEND FEES OR COMPLETED FORMASTO. THIS ADDRESS. SEND TO: Commissioner for Petents, P.O. Box 1450, Alexandria, VA 22313-1450.